Could a growth hormone drug help fight fatty liver disease?
NCT ID NCT03375788
First seen Nov 20, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study looked at whether tesamorelin, a drug that boosts growth hormone, can lower liver fat and improve liver health in 51 adults with nonalcoholic fatty liver disease (NAFLD) and obesity. Participants received either tesamorelin or a placebo for a period. The goal was to see if the drug could reduce liver fat and inflammation, which are key drivers of liver damage. The findings could offer a new way to manage NAFLD and lower related heart risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.